VIA-3196: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 48 healthy volunteers with mildly elevated LDL-C showed that once-daily 5, 20 and 50 mg doses of oral MDL-3196 for 14 days were well tolerated with no dose-related adverse events or liver enzyme changes reported. Relative to placebo, once-daily doses of MDL-3196 led to significant reductions in LDL-C of up to 30% (p<=0.05), 28% for non-HDL-C (p<=0.027) and 24% for apolipoprotein B (APOB) (p<=0.008). Data were presented at the American Heart Association meeting in Los Angeles. ...